[go: up one dir, main page]

MX2019009292A - Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. - Google Patents

Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.

Info

Publication number
MX2019009292A
MX2019009292A MX2019009292A MX2019009292A MX2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A
Authority
MX
Mexico
Prior art keywords
methods
prader
willi syndrome
amino
treatment
Prior art date
Application number
MX2019009292A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019009292A publication Critical patent/MX2019009292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan métodos de tratamiento de un trastorno convulsivo con ácido (1S,3S)-3-amino-4-(difluorometiliden)ciclopentan-1-carbo xílico o ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-en-1-c arboxílico (KT-II-115) o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Los métodos proporcionan composiciones terapéuticas que pueden utilizarse para mejorar uno o más de los síntomas de un trastorno convulsivo. Se proporcionan métodos de tratamiento del síndrome de Prader-Willi con ácido (1S,3S)-3-amino-4-(difluorometiliden)ciclopentan-1-carboxílico o acido (S)-3-amino-4-(difluorometilenil)ciclopent-1-en-1-carboxílic o (KT-II-115) o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Los métodos proporcionan composiciones terapéuticas que pueden utilizarse para mejorar uno o más de los síntomas del síndrome de Prader-Willi.
MX2019009292A 2017-02-08 2018-02-08 Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. MX2019009292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456320P 2017-02-08 2017-02-08
PCT/US2018/017382 WO2018148380A1 (en) 2017-02-08 2018-02-08 Methods of treating seizure disorders and prader-willi syndrome

Publications (1)

Publication Number Publication Date
MX2019009292A true MX2019009292A (es) 2019-09-13

Family

ID=63038393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009292A MX2019009292A (es) 2017-02-08 2018-02-08 Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.
MX2023009631A MX2023009631A (es) 2017-02-08 2019-08-05 Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009631A MX2023009631A (es) 2017-02-08 2019-08-05 Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.

Country Status (10)

Country Link
US (4) US20180221319A1 (es)
EP (1) EP3579826A4 (es)
JP (3) JP7607302B2 (es)
KR (3) KR20190111105A (es)
CN (1) CN110461319A (es)
AU (1) AU2018219861B2 (es)
CA (1) CA3051699A1 (es)
IL (2) IL310065A (es)
MX (2) MX2019009292A (es)
WO (1) WO2018148380A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP2019526544A (ja) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
CN112261938A (zh) 2018-02-08 2021-01-22 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途
KR20210009306A (ko) * 2018-03-29 2021-01-26 오비드 테라퓨틱스 인크. 눈 장애의 치료에서 (1s, 3s)-3-아미노-4-(디플루오로메틸리덴)시클로펜탄-1-카르복실산 및 (s)-3-아미노-4-(디플루오로메틸에닐)시클로펜트-1-엔-1-카르복실산의 용도
IL304270B2 (en) * 2018-06-07 2024-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
CN113496359B (zh) * 2021-07-13 2022-03-22 天津大学 一种多组合主客观均匀优化赋权风险评价方法
WO2024173750A2 (en) * 2023-02-17 2024-08-22 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) * 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
WO2009023601A2 (en) * 2007-08-11 2009-02-19 Argenis Llc Apparatus and methods for treating epilepsy using convection-enhanced delivery
WO2011106692A2 (en) * 2010-02-25 2011-09-01 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20140315992A1 (en) * 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
EP3341355B1 (en) 2015-10-09 2020-09-30 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Also Published As

Publication number Publication date
JP2024147737A (ja) 2024-10-16
WO2018148380A1 (en) 2018-08-16
KR20240110989A (ko) 2024-07-16
JP2020506240A (ja) 2020-02-27
US20230149332A1 (en) 2023-05-18
US20240173280A1 (en) 2024-05-30
KR20190111105A (ko) 2019-10-01
KR20240110084A (ko) 2024-07-12
JP7607302B2 (ja) 2024-12-27
MX2023009631A (es) 2023-08-28
JP2023025040A (ja) 2023-02-21
US20200000757A1 (en) 2020-01-02
EP3579826A4 (en) 2020-11-18
US20180221319A1 (en) 2018-08-09
IL268212B1 (en) 2024-02-01
CA3051699A1 (en) 2018-08-16
EP3579826A1 (en) 2019-12-18
IL268212B2 (en) 2024-06-01
CN110461319A (zh) 2019-11-15
US11918551B2 (en) 2024-03-05
AU2018219861A1 (en) 2019-08-15
IL268212A (en) 2019-09-26
AU2018219861B2 (en) 2022-03-31
IL310065A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
MX2019009292A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.
MX2022004734A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
MX2018005829A (es) Composiciones para tratar el cabello.
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
MX380866B (es) Composiciones y métodos para modular la expresión del factor b del complemento.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX381283B (es) Tratamiento de pénfigo.
GT201700107A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
MX2016010071A (es) Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
AR099307A1 (es) Sales de triazolo piridina para el tratamiento de trastornos inflamatorios
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2019000190A1 (es) Tratamiento y prevención de los trastornos del sueño.
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
PH12017500747B1 (en) Heterocyclic compound
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.